Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens

Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment

(2017) Meirong Huo et al.   JOURNAL OF CONTROLLED RELEASE

Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma

(2017) Kai-chao Feng et al.   Journal of Hematology & Oncology

Circulating and disseminated tumor cells: harbingers or initiators of metastasis?

(2017) Arko Dasgupta et al.   Molecular Oncology

Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers

(2017) Chengcheng Zhang et al.   MOLECULAR THERAPY

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

(2017) Andras Heczey et al.   MOLECULAR THERAPY

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

(2017) Frederick L. Locke et al.   MOLECULAR THERAPY

Development of CAR T cells designed to improve antitumor efficacy and safety

(2017) Janneke E. Jaspers et al.   PHARMACOLOGY & THERAPEUTICS

Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity

(2017) Akash Patnaik et al.   Cancer Discovery

DLBCL Responds Well to Anti-CD19 CAR Therapy

(2017)   Cancer Discovery

Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers

(2017) Kaichao Feng et al.   Protein & Cell

CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy

(2017) Nan Chen et al.   OncoImmunology

Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade

(2017) Inna Serganova et al.   Molecular Therapy-Oncolytics

HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma

(2017) Nabil Ahmed et al.   JAMA Oncology

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer

(2017) Kristen M. Hege et al.   Journal for ImmunoTherapy of Cancer

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment

(2017) Irene Scarfò et al.   Journal for ImmunoTherapy of Cancer

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines

(2017) Dina Schneider et al.   Journal for ImmunoTherapy of Cancer

Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview

(2016) C. H. J. Lamers et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

The immunomodulatory, antitumor and antimetastatic responses of melanoma-bearing normal and alcoholic mice to sunitinib and ALT-803: a combinatorial treatment approach

(2016) Kari A. Gaither et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors

(2016) Xiaojun Liu et al.   CANCER RESEARCH

From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain

(2016) Yanling Wu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response

(2016) Richard P. Junghans et al.   PROSTATE

Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects

(2016) Shengmeng Di et al.   Science China-Life Sciences

Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

(2016) Fengtao You et al.   Science China-Life Sciences

Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment

(2016) Luuk van Hooren et al.   Oncotarget

Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice

(2016) Qing Zhang et al.   Oncotarget

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells

(2016) E. Zah et al.   Cancer Immunology Research

Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

(2015) C. E. Brown et al.   CLINICAL CANCER RESEARCH

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases

(2015) S. C. Katz et al.   CLINICAL CANCER RESEARCH

Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma

(2015) Nengwang Yu et al.   INTERNATIONAL JOURNAL OF CANCER

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

(2015) Nabil Ahmed et al.   JOURNAL OF CLINICAL ONCOLOGY

A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD

(2015) Qing Zhang et al.   PLoS One

Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice

(2015) Fei-Ting Hsu et al.   Oncotarget

Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication

(2015) Oana Draghiciu et al.   OncoImmunology

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

(2014) Anna R Kwilas et al.   Journal of Translational Medicine

CD8+T cell–specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors

(2014) Jiemiao Hu et al.   Molecular Cancer

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment

(2014) Hui-Yen Chuang et al.   PLoS One

PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models

(2014) Gaia Zuccolotto et al.   PLoS One

A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma

(2014) Hirokazu Matsushita et al.   Journal for ImmunoTherapy of Cancer

Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer

(2013) D. Alizadeh et al.   CANCER RESEARCH

Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer

(2013) Y. Homma et al.   Clinical & Translational Oncology

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

(2013) L. B. John et al.   CLINICAL CANCER RESEARCH

Strategies to Improve the Clinical Performance of Chimeric Antigen Receptor-Modified T Cells for Cancer

(2013) Qing Zhang et al.   CURRENT GENE THERAPY

Adoptive immunotherapy for cancer

(2013) Marco Ruella et al.   IMMUNOLOGICAL REVIEWS

Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity

(2013) Mei-Ling Chen et al.   INTERNATIONAL JOURNAL OF CANCER

Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma

(2013) Meenakshi Hegde et al.   MOLECULAR THERAPY

Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells

(2013) Usanarat Anurathapan et al.   MOLECULAR THERAPY

T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

(2013) M. V. Maus et al.   Cancer Immunology Research

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

(2013) Zakaria Grada et al.   Molecular Therapy-Nucleic Acids

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

(2012) W. Haso et al.   BLOOD

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

(2012) B. G. Till et al.   BLOOD

Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma

(2012) Roniel Cabrera et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer

(2012) Stephanie K. Bunt et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems

(2012) Oktay Tacar et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

Gemcitabine enhances Wilms’ tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response

(2011) Akitaka Takahara et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control

(2011) M. Hong et al.   CANCER RESEARCH

Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma

(2011) Antonia Busse et al.   EUROPEAN JOURNAL OF CANCER

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells

(2010) C. H. J. Lamers et al.   BLOOD

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity

(2010) J. Vincent et al.   CANCER RESEARCH

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

(2010) K. N. Kodumudi et al.   CLINICAL CANCER RESEARCH

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination

(2010) Anamika Bose et al.   INTERNATIONAL JOURNAL OF CANCER

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

(2010) Rupal Ramakrishnan et al.   JOURNAL OF CLINICAL INVESTIGATION

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE